Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaroBAT trial of darolutamide with bipolar androgen therapy in metastatic castration-resistant prostate cancer
2025-521051-23-00Phase 2Authorised
- Sponsor
- Universität Münster
- Start
- Jul 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide and testosterone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Universität Münster. Primary endpoints: Progression-free survival and Quality of life until progression. Planned start Jul 2025; status: authorised.
02
Drugs
darolutamidetestosterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-521051-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521051-23-00.